Trump's Order Accelerates FDA Review of Ibogaine and Psychedelics

On April 18, 2026, President Trump signed an executive order to expedite U.S. federal reviews of psychedelics, including ibogaine, aimed at improving medical research and clinical trials. The FDA plans to issue national priority vouchers next week for three psychedelics, allowing for accelerated approval if aligned with national priorities. Ibogaine is currently classified as a high-risk drug and is banned federally, but advocates believe it could benefit conditions like PTSD and opioid addiction. This directive marks the FDA's first fast-tracking initiative for psychedelics, reflecting a shift in policy toward potential treatment options.